Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Teprotumumab shows promise in small chinese thyroid eye study

NCT ID NCT07085117

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This completed study looked at how well teprotumumab (TEPEZZA) works in real-world use for 5 Chinese patients with thyroid eye disease. The main goal was to see how many patients had a reduction in eye bulging (proptosis) after their last IV infusion. The study also collected basic information about the patients and their health at the start of treatment.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
teprotumumab (TEPEZZA)
What this could lead to
If successful, this could confirm that teprotumumab works in Chinese patients with thyroid eye disease, supporting its use in broader populations.
What could go wrong
This is a very small study (only 5 patients) and retrospective, so results may not apply to everyone. No new safety data beyond what is already known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

5 people

The number who actually took part.

Started

Jul 2025

Finished

Aug 2025

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Participants with TED that have received teprotumumab treatment in BOAO Pilot Zone.

Ages

18 to 120 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Receipt of at least 1 infusion of teprotumumab for treatment of the TED. * Obtained study specific informed consent form (ICF), if required. Exclusion Criteria: * Documentation of non-Chinese ethnicity.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Thyroid eye disease are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

endocrine exophthalmos Graves Ophthalmopathy

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Boao Vanguard Hospital

    Qionghai, Hainan, 571400, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.